Dr. Donald Morris

Research Interests:
novel therapeutics, translational approaches

Academic Background:
Ph.D. M.D. FRCPC (Medical Oncology)
Queen's University      University of Calgary

Position:
Associate Professor,
Department of Medicine and Oncology
Faculty of Medicine, Tom Baker Cancer Centre
Senior Scientist,
Translational Laboratories, Tom Baker Cancer Centre
Director of Oncology Training Programs,
University of Calgary

Research Interests:
Translational research involving viral oncolysis, apoptosis and graft engineering of stem cells.

Contact Information:
Phone: (403) 521-3166
Fax: (403) 283-1651
E-mail: donmorri@cancerboard.ab.ca

Member:
Southern Alberta Cancer Research Institute

Member:
Translational

Department:
Oncology, Division of Medical Oncology

Research Details:
As a translational researcher, my interests lie in bringing novel therapeutics into the clinic. My laboratory has interests in viral oncolysis and mechanisms therein, as well as graft engineering of autologous stem cell transplant products and interests in prostate carcinoma murine model systems.  Recently, we have been investigating the role of  immunotherapeutics in Breast/Prostate cancers using a novel viral vaccine approach.

Clinical Trials:
17119-A randomized double-blind placebo controlled study of subject with previously untreated extensive-stage small cell lung cancer with platinum plus etoposide chemotherapy
P.I.  Dr. D. Morris

ET743 STS-201.  A randomized phase I, multicenter, open label study of Yondelis by two different schedules in subjects with locally advanced or metastatic liposarcoma or leiomyosarcoma following treatment with anthracycline and Ifosfamide.  P.I. Dr. D. Morris

GSK615.  An open label, multicenter trial comparing 2 schedules of GW572016 as first line monotherapy in subjects with locally advanced or metastatic non-small cell lung cancer.  P.I. Dr. D. Morris

An open label multicenter randomized phase III study comparing combination IV topotecan/docetaxel to docetaxel alone in second line advanced non-small cell lung cancer.  P.I. Dr. D. Morris

20010145: A randomized , double blind, placebo controlled study of subjects with previously untreated extensive stage small cell lung cancer treated with platinum plus etoposide chemotherapy with or without darbopoetin alfa. P.I. Dr. D. Morris

A dose finding study of fixed dose vinorelbine and escalating doses ifosfamide, on days 1 and 8 in patients with advanced non-small cell lung cancer.  P.I. Dr. D. Morris.

10484-A 389:  an open - label, multicentre, randomized, Phase III Study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naïve patients with extensive disease-small cell lung cancer.  P.I. Dr D. Morris

10464-A: an open-label, multicentre, randomized, Phase III comparator study of active symptom control alone or in combination with oral topotecan in patients with relapsed SCLC. P.I. D. Morris

A6181004: A phase III, randomized, double blind. Placebo controlled study of SU011248 in the treatment of patients with Gleevec resistant or intolerant malignant gastrointestinal stromal tumour. P.I. Dr D. Morris

A phase II, multicentre trial comparing two schedules of GW572016 as first line monotherapy in subjects with advanced or metastatic non-small cell lung cancer. P.I.  Dr D Morris

CP02-0452:  Randomized phase III study of docetaxel or pemetrexed with or without cetuximab in patients with recurrent or progressive non-small cell lung cancer after platinum-based therapy. P.I. Dr. D. Morris 

B017704 (NSCLC):  A randomized, double-blind 2-stage phase III study of bevacizumab in combination with cisplatin and Gemcitabine versus placebo, cisplatin and Gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer, who have not received prior chemotherapy. P.I. D. Morris

Grant Funding: 
NCIC, ACB, CBCRF, CBCRA, and CPCRF.